Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

NASDAQLPCN
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 27, 2021Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteApr 9, 2021Open A preliminary proxy statement providing notification matters to be brought to a vote in HTML.Open A preliminary proxy statement providing notification matters to be brought to a vote in DOC file.Open A preliminary proxy statement providing notification matters to be brought to a vote in PDF file.Open A preliminary proxy statement providing notification matters to be brought to a vote in XLS file.
PX14A6GNotice of exempt solicitation. Definitive materialMay 20, 2020Open Notice of exempt solicitation. Definitive material in HTML.Open Notice of exempt solicitation. Definitive material in DOC file.Open Notice of exempt solicitation. Definitive material in PDF file.Open Notice of exempt solicitation. Definitive material in XLS file.